**Core Concept**
Zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI), is used in the prevention and treatment of HIV infection. It acts by inhibiting the reverse transcription of viral RNA into DNA, thus preventing the integration of viral genome into the host cell.

**Why the Correct Answer is Right**
In the case of accidental exposure to HIV-positive serum, zidovudine can be used as post-exposure prophylaxis (PEP) to prevent the establishment of HIV infection. This is because zidovudine can inhibit the replication of HIV, thereby reducing the amount of virus that can be integrated into the host cells. The use of zidovudine in this context is based on the concept of "hit-hard-hit-soon" - the sooner the treatment is initiated after exposure, the more effective it will be in preventing infection. Zidovudine works by being phosphorylated to its active form, zidovudine triphosphate, which then competes with the natural nucleotides for incorporation into the viral DNA, resulting in chain termination and inhibition of viral replication.

**Why Each Wrong Option is Incorrect**
**Option B:** Making the patient seronegative is not a realistic goal of zidovudine treatment, as it cannot completely eliminate the virus from the body. Zidovudine can only reduce the viral load to undetectable levels, but it cannot guarantee seroconversion to negative.
**Option C:** While zidovudine can delay the progression of disease, this is not its primary role in the context of accidental exposure to HIV-positive serum. In this scenario, the primary goal is to prevent infection, not to manage established disease.
**Option D:** This option is incorrect because zidovudine does have a role in the treatment of accidental exposure to HIV-positive serum, as described above.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that PEP should be initiated as soon as possible after exposure, ideally within 2-3 hours, and continued for 28 days to maximize its effectiveness.